| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6175953 | European Urology | 2015 | 7 Pages |
Abstract
Enzalutamide was active against prostate cancer and was well tolerated, even for up to 4 yr of treatment, supporting its potential for long-term use in men with prostate cancer. Fatigue was the most common side effect, occurring at varying degrees of severity in most patients.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Celestia S. Higano, Tomasz M. Beer, Mary-Ellen Taplin, Eleni Efstathiou, Mohammad Hirmand, David Forer, Howard I. Scher,